Patent Thickets in Biotechnology Innovation

Introduction

A patent thicket refers to a dense network of overlapping patents that a company or researcher may need to navigate to develop, manufacture or commercialise a single product. In biotechnology, thickets can arise around genetic engineering, gene-editing tools, therapeutic proteins, vaccines, diagnostic technologies and genetically modified crops.

Patent thickets may protect substantial research investment, but they can also increase licensing costs, create infringement risks, delay commercialisation and discourage smaller biotechnology companies. Their legal significance lies in balancing patent protection with competition, research access and public health.

1. Causes and Consequences of Patent Thickets

Overlapping patent claims: Different patent holders may claim related components, methods, formulations or applications involved in one biotechnology product.

Multiple ownership: Researchers may need licences from several institutions or companies before bringing a product to market.

Cumulative licensing costs: Separate royalties and negotiations can increase research and manufacturing expenses.

Litigation uncertainty: Disputes over claim scope, validity and infringement may delay investment and product launches.

Barriers to innovation: Start-ups and academic laboratories may lack the resources needed to negotiate multiple licences or defend infringement claims.

Patent thickets are not automatically unlawful. The relevant question is whether individual patents are valid and enforceable and whether licensing or commercial conduct violates applicable patent or competition law.

2. Legal Framework in India

The Patents Act, 1970, provides several safeguards relevant to biotechnology patent thickets.

Section 3(c): Excludes the mere discovery of a scientific principle or the discovery of a living or non-living substance occurring in nature.

Section 3(d): Restricts patents for certain new forms of known substances unless the statutory efficacy requirement is met.

Section 3(j): Excludes plants and animals, in whole or in part, other than microorganisms, along with seeds, varieties, species and essentially biological processes for producing or propagating plants and animals.

Section 84: Permits compulsory licensing when the statutory conditions are satisfied, including specified circumstances involving public requirements, affordability and non-working in India.

Section 64: Provides grounds for revocation of patents, including specified defects in patentability.

These provisions can help prevent unjustified exclusivity and provide routes to challenge or address problematic patents.

Government of India

+1

3. Important Case Laws

A. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

The US Supreme Court considered patents covering BRCA1 and BRCA2 genes associated with increased risks of breast and ovarian cancer. It held that naturally occurring DNA does not become patent-eligible merely because it has been isolated. However, synthetically created complementary DNA (cDNA) may be patent-eligible where it is not naturally occurring, subject to applicable legal requirements.

Legal principle: Patent protection cannot automatically extend to discoveries of naturally occurring genetic material. The decision is relevant to preventing overly broad claims that could restrict subsequent genetic research.

National Agricultural Law Center

B. Monsanto Technology LLC v. Nuziveedu Seeds Ltd., (2019) 3 SCC 381

The dispute concerned Monsanto's patented Bt cotton technology and its licensing arrangements with seed companies. Questions arose regarding patentability under Section 3(j), the technology's biological characteristics and the validity of the patent. The Supreme Court set aside the Delhi High Court's summary adjudication and remanded the matter for determination through appropriate proceedings.

Legal principle: Complex biotechnology patent disputes involving scientific evidence, statutory exclusions and claim interpretation may require detailed examination rather than summary determination.

WIPO

C. Bowman v. Monsanto Co., 569 U.S. 278 (2013)

The US Supreme Court considered whether a farmer could reproduce patented genetically engineered soybeans by planting harvested seeds without the patent holder's permission. The Court held that patent exhaustion did not authorise the farmer to make new copies of the patented invention.

Legal principle: Patent exhaustion does not generally permit the unauthorised creation of new patented copies. In biotechnology, this principle illustrates how patent rights can affect the reproduction and commercial use of biological technologies.

National Agricultural Law Center

4. Measures to Address Patent Thickets

Patent thickets can be managed through careful patent searches, independent validity assessments, cross-licensing, transparent patent pools, research exemptions where available and compulsory licensing when statutory requirements are met. Clearer claim drafting and competition-law scrutiny of restrictive licensing practices can also reduce unnecessary barriers.

Conclusion

Patent thickets in biotechnology create challenges for innovation, investment and access to technology. The decisions in Myriad Genetics, Monsanto v. Nuziveedu and Bowman v. Monsanto illustrate the importance of defining patentable subject matter and the limits of patent rights. A balanced approach should protect genuine biotechnology inventions while preventing unjustified exclusivity, excessive licensing barriers and restrictions on legitimate scientific development.